James Rodberg Sells 6,902 Shares of Sight Sciences (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CFO James Rodberg sold 6,902 shares of the stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $5.36, for a total transaction of $36,994.72. Following the sale, the chief financial officer directly owned 224,037 shares in the company, valued at $1,200,838.32. This trade represents a 2.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Sight Sciences Trading Down 2.4%

NASDAQ SGHT opened at $5.35 on Wednesday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 5.48 and a current ratio of 5.86. Sight Sciences, Inc. has a one year low of $3.11 and a one year high of $9.24. The company has a 50-day simple moving average of $4.97 and a 200-day simple moving average of $5.29. The firm has a market capitalization of $291.09 million, a PE ratio of -7.54 and a beta of 2.38.

Sight Sciences (NASDAQ:SGHT) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.05). Sight Sciences had a negative return on equity of 52.34% and a negative net margin of 46.83%.The business had revenue of $19.70 million for the quarter, compared to analyst estimates of $18.46 million. On average, equities analysts forecast that Sight Sciences, Inc. will post -0.6 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Citigroup boosted their price objective on Sight Sciences from $4.35 to $5.15 and gave the company a “neutral” rating in a research report on Thursday, May 28th. Weiss Ratings lowered Sight Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, May 11th. Five research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Sight Sciences has an average rating of “Hold” and a consensus price target of $8.14.

Hedge Funds Weigh In On Sight Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Integral Health Asset Management LLC bought a new position in Sight Sciences during the 4th quarter valued at $3,370,000. Invesco Ltd. bought a new stake in shares of Sight Sciences in the 4th quarter worth $2,791,000. Walleye Capital LLC acquired a new stake in shares of Sight Sciences in the fourth quarter valued at $2,332,000. Informed Momentum Co LLC acquired a new stake in shares of Sight Sciences in the fourth quarter valued at $1,299,000. Finally, Americana Partners LLC boosted its stake in Sight Sciences by 12.1% during the fourth quarter. Americana Partners LLC now owns 1,378,980 shares of the company’s stock valued at $10,935,000 after buying an additional 149,161 shares in the last quarter. 55.51% of the stock is currently owned by institutional investors and hedge funds.

More Sight Sciences News

Here are the key news stories impacting Sight Sciences this week:

• Negative Sentiment: CEO Paul Badawi sold 28,684 shares, the largest disclosed insider transaction in the batch, which may suggest reduced insider confidence. Sight Sciences (NASDAQ:SGHT) CEO Paul Badawi Sells 28,684 Shares of Stock
• Negative Sentiment: CFO James Rodberg sold 6,902 shares, adding to the leadership-level selling pressure. Sight Sciences (NASDAQ:SGHT) CFO Sells 6,902 Shares
• Negative Sentiment: CTO David Badawi, EVP Brenton Taylor, and insider Jeremy B. Hayden also sold shares, reinforcing the pattern of insider reductions across the company. Insider Selling: Sight Sciences (NASDAQ:SGHT) CTO Sells $40,873.18 in Stock Sight Sciences (NASDAQ:SGHT) EVP Sells $15,333.18 in Stock

Sight Sciences Company Profile

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.